Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

70.30USD
16 Oct 2018
Change (% chg)

$0.84 (+1.21%)
Prev Close
$69.46
Open
$70.06
Day's High
$70.38
Day's Low
$69.75
Volume
217,649
Avg. Vol
2,697,578
52-wk High
$72.89
52-wk Low
$52.83

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.90
Market Cap(Mil.): $190,049.70
Shares Outstanding(Mil.): 2,659.52
Dividend: 0.48
Yield (%): 2.69

Financials

  MRK.N Industry Sector
P/E (TTM): 49.06 29.75 32.14
EPS (TTM): 1.46 -- --
ROI: 5.65 13.18 12.83
ROE: 10.95 15.14 14.95

Cancer center CEO leaves Merck board after disclosure scandal

NEW YORK The chief executive of Memorial Sloan Kettering Cancer Center, Craig Thompson, resigned from the boards of drugmaker Merck & Co Inc and lab services firm Charles River Laboratories International Inc on Tuesday, following media investigations about the U.S. center's ties to the pharmaceutical industry.

Oct 02 2018

UPDATE 1-Cancer center CEO leaves Merck board after disclosure scandal

NEW YORK, Oct 2 The chief executive of Memorial Sloan Kettering Cancer Center, Craig Thompson, resigned from the boards of drugmaker Merck & Co Inc and lab services firm Charles River Laboratories International Inc on Tuesday, following media investigations about the U.S. center's ties to the pharmaceutical industry.

Oct 02 2018

Cancer center CEO leaves Merck board after disclosure scandal

NEW YORK, Oct 2 Craig Thompson, chief executive of Memorial Sloan Kettering Cancer Center, resigned from the board of drugmaker Merck & Co Inc on Tuesday, after questions about the cancer center's ties to the pharmaceutical industry.

Oct 02 2018

Merck's Frazier to remain CEO of the U.S. drugmaker beyond 2019

Merck & Co Inc Chief Executive Officer Kenneth Frazier will remain in the role beyond 2019, the drugmaker said on Wednesday, after it scrapped a policy requiring its CEOs to retire at the age of 65.

Sep 26 2018

UPDATE 5-Merck's Frazier to remain CEO of the U.S. drugmaker beyond 2019

Sept 26 Merck & Co Inc Chief Executive Officer Kenneth Frazier will remain in the role beyond 2019, the drugmaker said on Wednesday, after it scrapped a policy requiring its CEOs to retire at the age of 65.

Sep 26 2018

Merck CEO to stay post 65 after company amends retirement policy

Sept 26 Drugmaker Merck and Co Inc said on Wednesday that its board voted to rescind a policy requiring its head to retire at 65, a move that will permit current Chief Executive Officer Kenneth Frazier to remain in the role beyond next year.

Sep 26 2018

Roche's Tecentriq, trailing rival drugs, lifts lung cancer survival

ZURICH A drug cocktail with Roche's Tecentriq added two months to small-cell lung cancer patients' lives, according to a study, aiding the Swiss group's bid to win approval in a niche disease area before rivals that now dominate the immunotherapy market.

Sep 25 2018

UPDATE 1-Roche's Tecentriq, trailing rival drugs, lifts lung cancer survival

* Rivals Keytruda, Opdivo have overshadowed Roche drug (Adds comment from company, market reaction, comment from analyst)

Sep 25 2018

Roche's Tecentriq adds 2 months to lung cancer patients' lives - study

ZURICH, Sept 25 A drug cocktail with Roche's Tecentriq added two months to small-cell lung cancer patients' lives, potentially aiding the Swiss company's bid to win approval in a niche disease area before rivals that now dominate the immunotherapy market.

Sep 25 2018

Merck's Keytruda clocks up new win as EU approves chemo cocktail

LONDON Merck & Co's key cancer drug Keytruda has been approved for use in Europe in combination with chemotherapy in previously untreated lung cancer patients, marking a further advance for the product after uncertainty about its EU prospects a year ago.

Sep 10 2018

Competitors

Earnings vs. Estimates